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and literature review
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Abstract 
Background: Solitary fibrous tumour (SFT) is a rare soft tissue sarcoma with a low metastatic potential. A higher 
metastatic rate is observed in the high-grade/dedifferentiated variant. The most common expected site of distant 
spread are the lungs and the liver. Bone involvement is generally viewed as a late stage of disease spread. We report 
on a retrospective series of SFT patients relapsing with a single distant bone recurrence as first metastatic event, with-
out evidence of other organ involvement.
Case presentation: All patients affected by a single distant bone metastasis from SFT as first distant event, without 
any evidence of other site of metastasis, observed at our Institution, were considered. Bone involvement from SFT 
was pathologically assessed in all cases and confirmed by expert pathologists. A total of six patients were retrospec-
tively identified. Primary tumour arose from the meninges in four patients, from soft tissues in two. Bone metastases 
were located to the vertebrae, the hip, the acetabulum and the rib. In all cases, bone relapse was the first event, with 
one patient presenting a local relapse. Median time from the primary tumour and the evidence of bone relapse was 
40 months (range 0–58). In 2/6 patients bone metastasis was treated with radiotherapy (RT), in 2/6 with surgery, in 2/6 
with surgery plus RT. At a median follow-up of 55 months (range 23–88), 5/6 patients are alive (2/5 without disease, 
3/5 with multicentric metastatic disease) and one is dead of disease. 2/6 patients did not relapse after the treatment 
of the bone metastasis.
Conclusions: This small series in a relatively rare histology suggests that isolated, possibly late, bone metastases are a 
plausible scenario, in particular in meningeal SFT. Notably, new bone lesions in a patient with a history of SFT should 
be always investigated. Exclusive local treatments may be an option, though collection of such series would be 
needed to define the best treatment strategy.
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Background
Solitary fibrous tumour (SFT) is a very rare sarcoma, 
most frequently occurring in middle-aged patients. SFT 
can occur in several anatomic sites like meninges, peri-
toneum, head and neck, extremities, and viscera [1–3]. 
Recently also primary SFTs arising from the bone have 
been reported [4]. SFT is characterized by a specific 
NAB2–STAT6 gene fusion which is responsible for the 
nuclear expression of the chimeric oncoprotein STAT6, 
which is the immunohistochemical hallmark of SFT [5–8] 
and helps in differential diagnosis. Of note, dedifferenti-
ated SFT may lose the protein expression while retaining 
the fusion gene [9]. SFTs are known for the low tendency 
of recurrence and the low metastatic potential after com-
plete resection (10–15 %), even if a higher metastatic rate 
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(40  %) has been described in case of pleomorphic/dedi-
fferentiated SFT [10, 11]. Recurrence may happen many 
years after the initial diagnosis [12]. As for all other sar-
comas, the most frequent and initial site of metastasis 
is the lung, followed by the liver [13]. Bone involvement 
is reported in the late phase of the disease, in patients 
already affected by lung lesions [12].
We report on a retrospective series of SFT patients 
who suffered from a single distant bone recurrence as 
their first metastatic event, without evidence of any other 
organ involvement.
Case presentation
From May 2014 to April 2016 at the Fondazione IRCCS 
Istituto Nazionale Tumori Milan, Italy, we observed 
five patients with a diagnosis of SFT relapsed with sin-
gle bone metastasis plus an additional case whose bone 
metastasis was synchronous to the primary tumour.
Bone involvement from SFT was pathologically 
assessed in all cases and final diagnosis of bone relapse 
from SFT was confirmed by expert pathologists bas-
ing on morphologic and immunohistochemical features, 
with STAT6 nuclear immunopositivity, and by compar-
ing the metastatic tissue with the primary tumour.
Disease status was assessed in all the patients by whole 
body CT scan, MRI and/or CT of the primary tumour 
site. A bone scan ruled out the presence of other meta-
static bone lesions (Fig. 1).
Patient characteristics are summarized in Table 1. Pri-
mary SFT arose from the meninges in four patients, while 
in the soft tissues of the left thigh and left gluteus in two. 
Pathological centralized review of the primary tumour 
confirmed a diagnosis of malignant SFT in all the cases 
but one that was consistent with a classic SFT. The bone 
lesions were all consistent with a diagnosis of malignant 
SFT, with evidence of progression from a classic SFT 
towards a malignant SFT in one (Figs. 2,3).  
Bone metastases were mainly detected by the clinical 
complaint of pain, since a bone scan was not foreseen in 
the follow-up plan of these patients. Median time from 
the primary tumour diagnosis and the evidence of bone 
relapse was 40 months (range 0–58). In five cases, bone 
relapse was the first event while one patient presented 
with a synchronous single bone lesion (case 6 in Table 1).
All the patients received a definitive treatment of the 
bone lesion, with curative intent. A complete surgical 
resection of the bone metastasis was performed in four 
cases, followed by complementary radiotherapy in two 
cases. Radiotherapy was given in two cases.
At a median follow-up of 55  months (range 23–88), 
five of six patients are alive (2/5 without disease, 3/5 
with multicentric metastatic disease) and one is dead of 
disease. Two of six patients (one treated with definitive 
RT and one with surgery plus RT) did not suffer of any 
tumour relapse after the treatment of the bone metasta-
sis, at a follow-up of 51 and 56 months (Table 1).
Discussion
This retrospective analysis reports on a series of six 
patients affected by a single solitary bone metastasis 
from SFT as first metastatic event. This small series in a 
relatively rare histology shows that isolated, possibly late, 
bone metastases are a plausible scenario, in particular in 
meningeal SFTs.
All patients were treated with a curative intent. Two of 
them are still disease free at 51 and 56 months.
In the literature, the most common sites of metastasis 
in SFT patients were reported to be the lung and the liver 
[12, 14–31]. In addition, there are few case reports of 
SFTs, mostly arising from the meninges and pleura, pre-
senting with multiple late distant bone metastases that 
followed the prior evidence of lesions located to the lung 
and to the liver. To our knowledge there are only two 
reports of SFTs relapsed with a single late bone metas-
tasis and no extra-skeletal [32, 33]. Notably in both cases 
primary tumour was located to the meninges.
Our study confirms that isolated bone metastasis can 
occur in SFT. To note, in our series, in two of four cases 
the primitive tumour arose from the soft tissue.
Recently also primary SFT arising from the bone have 
been reported [26]. In case of a single bone lesion con-
sistent with SFT a past or present primary tumour needs 
always to be ruled out.
In our series, median time from the primary tumour 
and the appearance of bone relapse was about 3  years, 
while published cases are reported after a long interval 
from the primary [32, 33].
Fig. 1 Single bone metastasis from meningeal SFT (patient 1 in 
Table 1): CT scan (venous phase after contrast medium) shows a solid 
lesion characterized by homogeneous contrast enhancement at the 
level of the seventh left rib
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All our patients received a local treatment of the bone 
metastasis with a curative intent. This could be consid-
ered an overtreatment as the standard of care of bone 
metastasis is offered with a palliative intent. Curative sur-
gery was selected in four patients, followed by comple-
mentary radiotherapy in two cases (cases 3, 4, Table  1), 
while radiotherapy was given in two cases. However, it 
is interesting to note that in two cases with a prolonged 
follow-up the tumour has not yet relapsed. Yet to be con-
firmed on a larger prospective series, this suggests that 
in case of single bone metastasis a local treatment with 
curative intent may be an option.
In addition, in one of the two cases, the selected treat-
ment was definitive RT alone suggesting that radiation 
treatment can be an alternative to surgery when mor-
bidity is an issue. No patients received a systemic treat-
ment for the single bone lesion; chemotherapy was given 
later in two patients who relapsed to multiple sites. SFTs 
show a low sensitivity to conventional cytotoxic chemo-
therapy [34, 35]. Recently, systemic therapy has focused 
on molecularly targeted therapies reporting some activ-
ity of antiangiogenics (bevacizumab in combination 
with temozolomide, sorafenib, sunitinib and pazopanib) 
[35–37].
There is no consensus on the optimal routine follow-up 
policy of sarcomas [38]; although SFTs presenting with 
a single bone metastasis seem to be relatively rare, this 
series suggests that a bone scan should be included in 
the staging of SFT patients and in case of bone pain in a 
patient with a history of SFT.
In one case we observed a bone lesion progressing 
towards a more aggressive variant of SFT. This underlies 
once more the limits of the classification available to date 
[39]. None of our cases showed, at the time of the skeletal 
progression, a biological shift towards a high-grade dedif-
ferentiated SFT. However, some of the cases showed an 
initial loss of STAT6 nuclear positivity in the bone metas-
tasis, suggestive for a more aggressive potential. It is now 
described in the literature that immunohistochemical 
positivity for STAT6 may be lost in some SFTs while the 
fusion NAB2–STAT6 is retained [9]. To rule-out SFT 
diagnosis in these cases the demonstration of transloca-
tion is needed.
Conclusion
This small series in a rare sarcoma subtype suggests that 
isolated, skeletal metastases are a possible event in both 
meningeal and extrameningeal SFTs. On this basis bone 
lesions or symptoms in a patient with a history of SFT 
should be always investigated. Potentially curative local 
treatments may be an option, although a larger series 
is needed to define the best treatment strategy for such 
patients.
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